Isolated ambulatory hypertension is a condition characterized by elevated ambulatory but normal clinic blood pressure (BP), and has been reported to be associated with increased cardiovascular risk in untreated subjects. However, little is known about the relationship between this condition and intermediate end points such as target organ damage (TOD) in treated hypertensives. We investigated the impact of isolated ambulatory hypertension on left ventricular hypertrophy (LVH) and microalbuminuria (MA) in a selected sample of treated nondiabetic hypertensives with effective and prolonged clinic BP control (BPo140/90 mmHg). Clinic BP measurements, routine diagnostic procedures, echocardiography and 24-h urine collection for MA, were undertaken in 80 patients (mean age 5378 years) with essential hypertension attending our hospital outpatient centre at baseline and after an average follow-up of 30 months. At follow-up evaluation BP status was assessed by self-measurement of BP and ambulatory BP monitoring (ABPM). At the follow-up visit, 51 out of 80 patients (63.7%) reached a BP control according to ABP (average daytime BPo132/85 mmHg) criteria (group I) whereas the remaining 29 did not (group II); home BP was controlled (BPo135/85 mmHg) in all members of group I and in 86% of group II. In the overall study population, mean Sokolow voltage, LV mass index (LVMI) and urinary albumin excretion (UAE) decreased compared to baseline from 24.175.0 to 18.975.1 mm (Po0.05), 115.6724.1 to 97.7721.6 g/m 2 (Po0.01), 11.8723.7 to 5.8714.9 mg/24 h (Po0.05), respectively. The prevalence of ECG LVH, altered LV patterns and MA fell from 7.5 to 2.5% (P ¼ NS), from 45 to 25 (Po0.01) and from 13.7 to 5.1% (Po0.05), respectively. However, when data were analysed separately for the two groups a significant decrease of echo LVH and MA was found only in patients with controlled ABP. LVMI and MA decreased from 117.1723.1 to 95.9722.1 g/m 2 (Po0.01) and 12.8724.7 to 4.175.7 mg/24 h (Po0.05) in group I, and from 114.1724.8 to 102.3720.3 (P ¼ NS) and 11.9722.1 to 6.3718.1 mg/24 h (P ¼ NS) in group II. In conclusion, in the present study isolated ambulatory hypertension in treated patients is associated with a lack of regression in cardiac and extracardiac TOD, suggesting that a tight BP control throughout the 24 h plays a key role in lowering hypertension-induced structural and functional alterations at cardiac and renal level.
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Introduction
Failure to achieve target blood pressure (BP) may explain the higher prevalence of target organ damage (TOD) and the greater cardiovascular risk in treated hypertensive patients compared to normotensive subjects. 1, 2 Effective and prolonged BP normalization is the most powerful means for preventing and reducing hypertension-related preclinical complications at cardiac, large artery and microvascular level, and reducing cardiovascular events. It has been clearly shown that several markers of cardiac and extracardiac TOD, such as electrocardiographic or echocardiographic left ventricular hypertrophy (LVH), 3, 4 proteinuria or microalbuminuria 5, 6 and carotid artery thickening or plaques 7, 8 are powerful predictors for cardiovascular morbidity and mortality. A large body of evidence supports the view that ambulatory blood pressure (ABP) correlates more closely than clinic BP with TOD. 9, 10 Similarly, population-based prospective studies have shown that ABP better predicts than clinic BP measurements the risk of subsequent cardiovascular events. 11, 12 It has been also demonstrated that home BP measurement, providing multiple BP records under relatively stable conditions and in the absence of a 'white coat effect', has a superior clinical and prognostic value than office determination. 13, 14 The growing use of ABP monitoring (ABPM) or home BP measurement, in addition to conventional clinic measurement, for defining BP status has identified four BP patterns: true normotension, sustained hypertension, 'white coat hypertension' and its reverse phenomenon, the so-called 'white coat normotension' or isolated ambulatory hypertension. 15 The latter condition (elevated ambulatory but normal clinic BP) may have important clinical and prognostic implications in both untreated 16 and treated subjects. 17 To date, little is known about the prevalence of this phenomenon and its relationship with intermediate end points such as TOD in treated hypertensives.
Therefore, the aim of this study was to assess the impact of isolated ambulatory hypertension on LVH and microalbuminuria in a selected group of treated nondiabetic essential hypertensives with prolonged and effective BP control according to clinic criteria (BPo140/90 mmHg), regularly followed up in the outpatient clinic of the hypertension centre of University of Milan at the Ospedale Maggiore.
Methods

Study population
A total of 80 essential hypertensive patients on antihypertensive medications for at least 24 months and attending the outpatient clinic of our hypertension centre for a follow-up visit were selected for the study during a 6-month period between January and June 2003. All these patients had been previously included in the Evaluation Target Organ Damage in Hypertension (ETODH), an observational crosssectional study of the prevalence of hypertensionrelated TOD and concomitant cardiovascular risk factors aimed at estimating the total cardiovascular risk, according to the recommendations of the WHO/ISH 1999 and ESH/ESC 2003 hypertension guidelines. 18, 19 From January 1999 to June 2003, a total of 2250 treated and untreated (high BP defined as a SBPX140 mmHg and/or DBPX90 mmHg) subjects were included in this survey. The main exclusion criteria were secondary hypertension, history or evidence of congestive heart failure, previous myocardial infarction and stroke, cardiac valve disease, history of coronary bypass, atrial fibrillation, renal insufficiency, and major noncardiovascular diseases. In this survey, all subjects underwent the following procedures: clinic BP measurement, routine blood chemistry, urinalysis, electrocardiogram, 24-h urine collection for microalbuminuria, nonmydriatric retinography and cardiovascular ultrasonography.
For the present analysis, patients fulfilled further specific selection criteria: (1) satisfactory blood pressure control (BPo140/90 mmHg) during the past 12 months, confirmed by the study visit at outpatient clinic; (2) absence of diabetes mellitus, obesity (BMIX30 kg/m 2 ) and current smoking; (3) age o65 years; (4) familiarity with self-measurement of BP at home.
Diagnostic procedures included: (1) repeated BP measurements; (2) a 12-lead electrocardiogram at rest; (3) routine blood chemistry and urinalysis; (4) 24-h urine collection for microalbuminuria; (5) an echocardiogram undertaken before starting therapy (in 30 patients) or before substantial changes in previously ineffective therapeutic regimens (50 patients) (baseline data) and after a follow-up of 30 months (range [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . During this period, BP status was assessed by self-measurement of BP and ABPM. Follow-up was mostly handled by the medical team of our outpatient clinic, in cooperation with the patients' family doctors. Antihypertensive management was driven by clinic BP values recorded in the office.
Clinic blood pressure measurement BP was measured in the outpatient clinic by a physician with a mercury sphygmomanometer (first and fifth phases of Koroktoff sounds taken as systolic blood pressure (SBP) and diastolic blood pressure (DBP), respectively) after the subjects had comfortably rested for 5 min in the sitting position. Three measurements were taken at 1-min intervals, and the average was used to define clinic SBP and DBP.
Self-measured home BP
Self-measurement was performed by all patients with a successfully tested and previously calibrated fully automatic, oscillometric device (A&D UA-767; A&D Company Ltd, Tokyo, Japan), with automatic inflation and deflation and a digital display of BP and heart rate (HR). 20 This digital BP monitor stores up to 126 BP measurements, and is equipped with an interface for connection to a computer. The software can be used for statistical analysis, as well as for a clinical report for the patient. The physicians in charge of the trial instructed each subject how to fit the cuff and measure BP and HR with the monitor three times a day at specific time intervals: morning (between 08:00 and 09:00), afternoon (between 16:00 and 17:00) and evening (between 20:00 and 22:00), in the sitting position after a 5 min rest, over a period of 1 week. 21 An average home BP of 134/84 mmHg was considered as the upper limit of normality according to the current recommendations by the 2003 ESH/ESC hypertension guidelines.
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Ambulatory blood pressure monitoring Twenty-four hour ABPM was carried out on the nondominant arm using a Spacelabs 90207 device Ambulatory hypertension and changes in treated hypertensive patients C Cuspidi et al (Spacelabs Inc., Richmond, Washington, USA). The device was set to obtain BP readings at 15-min intervals during the day (07:00-23:00) and at 20-min intervals during the night (23:00-07:00). The time at which the device was applied was the same (71 h) in all patients. The patients were instructed to attend their usual day-to-day activities but to keep still at the times of measurements; all were asked to go to bed no later than 23:00 and arise not before 07:00.
Only ABP recordings with a minimum of 80% valid readings obtained within 24 h were accepted. The recording was then analysed to obtain 24 h, daytime and night time average SBP, DBP and HR. An average daytime ambulatory BP of 131/84 mmHg was considered as the upper limit of normality, according to the results of the PAMELA study. 22 The accuracy of both ambulatory and home BP monitoring devices was checked by multiple comparison with sphygmomanometer values by means of Y tube.
Electrocardiography
Standard 12-lead electrocardiogram was recorded at 25 mm/s velocity, using 1 mV/cm calibration. Two experienced cardiologists, blinded to clinical information, evaluated all tracings in order to detect LVH according to Sokolow-Lyon voltage criterion: sum of amplitude of S wave in V1 and R in V5 or V6 435 mm. 23 Echocardiography M-mode, two-dimensional and Doppler echocardiographic examinations were performed using commercially available instruments (ATL HDI 3000 and 5000, Bothell, Washington, USA) equipped with a 2.25 MHz imaging transducer. End-diastolic and end-systolic left ventricular internal diameter (LVIDd, LVIDs), interventricular septum thickness (IVST) and posterior wall thickness (PWT) were calculated from two-dimensionally guided M-mode tracing and measured during three to five consecutive cycles according to the Penn Convention. 24 Left ventricular mass was estimated by Devereux's formula and normalized to body surface area (BSA). 25 Patterns of left ventricular geometry were defined according to Ganau et al. 26 Left ventricular systolic function was assessed by endocardial fractional shortening [(LVIDdÀLVIDS)/LVIDd]. Left ventricular filling was assessed by recording mitral flow by standard pulsed Doppler technique and the following parameters were considered: early diastolic peak flow velocity (E), late diastolic flow velocity (A) and the ratio of the early to late peak (E/A ratio). LVH was defined as LVMI equal or exceeding 125 g/m 2 in men and 110 g/m 2 in women.
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Interobserver error for LVMI, determined by comparing 40 echocardiograms (50% of the overall study population), read by two skilled sonographers (CC and SM) was 7.9%; intraobserver error was 6.4% for CC and 7.0% for SM.
Microalbuminuria
Twenty-four-hour urinary albumin concentration was measured by a commercially available radioimmunoassay kit (Sclavo SPA, Cinisello Balsamo, Italy). The detection limit of the method was 0.5 mg/l. Microalbuminuria was defined as a urinary albumin excretion (UAE) X30 mg/24 h and o300 mg/24 h. 19 
Statistical analysis
Statistical analysis was performed by the SAS System (version 6.12; SAS Institute Inc., Cary, NC, USA). Values were expressed as means7s.d. or as percentages. Means were compared by the Student's t-test for independent samples. Analysis of categorical data was carried out with the w 2 test or Fischer's exact test when appropriate. The differences within groups were tested using ANOVA. Correlations were obtained by using Pearson's equation. The limit of statistical significance was set at Po0.05.
Results
Baseline data
The clinical characteristics of the whole study population reported in Table 1 refer to the time of their enrollment in the ETODH registry (baseline data). Out of the 80 hypertensive patients included in the study, 45 were men. The mean clinic BP was 149.6711.7/95.675.8 mmHg. Out of 80, 26 (32.5%) subjects were found to have LVH as defined by echocardiographic criteria and six (7.5%) according to electrocardiographic criteria. In addition, LV concentric remodelling was present in 10 patients (12.5%). Microalbuminuria was found in 11 patients (13.7%). In all, 30 patients were untreated and 50 had unsatisfactory control by their therapeutic regimens.
Follow-up data
In 51 patients (63.7%), mean daytime BP was o132/ 85 mmHg, and this group was considered controlled according to ABP criteria (group I); in the remaining 29 patients (uncontrolled), the average daytime BP values were equal or higher than this cutoff (group II). Table 2 summarizes the demographic and clinical characteristics for the two groups. Age, BMI, known duration of hypertension, prevalence of overweight, serum glucose and serum total cholesterol did not differ significantly between the two groups, whereas the percentage of patients with Ambulatory hypertension and changes in treated hypertensive patients C Cuspidi et al uncontrolled BP was numerically, but not significantly, higher in men than in women.
Clinic, seated BPs were not significantly different between the two groups (124/80 vs 124/82 mmHg), although diastolic BP tended to be lower (P ¼ 0.05) in group I. Average home BP, 24 h and night time ABP, in addition to daytime ABP, were all significantly lower in group I (Table 3 ). In terms of treatment, the prevalence of combination therapy (with two or more drugs) was higher in group I than in group II (75 vs 59%, P ¼ 0.05); the use of ACE inhibitors or Angio II Antagonists was nonsignificantly greater in controlled (71%) than in uncontrolled patients (59%).
LVMI, IVS, PWT (Po0.05) and RWT (Po0.05) tended to be lower in controlled patients (Table 4) . In addition, when LV echocardiographic data were analysed in a categorical way, as the presence or absence of altered patterns of LV structure and geometry (LVH and LV concentric remodelling), the prevalence of altered patterns was significantly lower in controlled than in uncontrolled (19.5 vs 34.4%, Po0.01) patients. The endocardial fractional shortening, an approximate index of LV systolic performance, and early/late mitral flow velocity ratio were similar in groups I and II.
The prevalence of subjects with microalbuminuria (UAE X30 mg/24 h) was lower in group I than in group II (3.9 vs 10.3%, Po0.05); while the difference in mean UAE (4.175.7 vs 6.8.718.3 mg/24 h) failed to achieve statistical significance.
Changes in TOD in patients with and without ABP control
At the follow-up evaluation, in the overall study population, mean Sokolow-Lyon voltage, LVMI and Table 5 shows clinical characteristics, continuous and categorical variables of TOD at baseline and during the follow-up period in controlled and uncontrolled patients.
In the whole study group, modest but significant statistical correlations were found between reductions in LVMI and clinic SBP/DBP (r ¼ 0.30 for SBP, Po0.01 and r ¼ 0.26 for DBP, Po0.01).
Discussion
Our data provide a new piece of information on cardiac and extracardiac TOD in middle-aged nondiabetic essential hypertensive subjects with achieved clinic BP control by long-term antihypertensive therapy. In our selected population, about one-third of patients with clinic normotension had daytime systolic or diastolic BP values that exceeded previously published cutoff values. 22 The following aspects of our findings deserve to be discussed. First, the more important aspect of our study, extending and refining previous evidence, is that in treated patients with isolated ambulatory hypertension, the decrease of LV mass and normalization of altered LV patterns (LVH or LV concentric remodelling), defined according to well prognostically validated sex-specific criteria, was significantly lower than in those with both office and ambulatory BP control. The variations in LV involvement seen, respectively, in patients with and without controlled BP during daily life was associated with a similar trend in 24-h UAE, and this finding indicates that parallel favourable changes in LV structure and in renal endothelial dysfunction may occur during long-term antihypertensive treatment. Second, patients with and without isolated ambulatory hypertension did not differ in age, known duration of hypertension, clinic BP, BMI or prevalence of overweight, serum glucose, serum cholesterol and smoking habit, whereas the percentage of subjects with uncontrolled ABP was higher in men than in women. These findings are not in line with previous studies that reported an association between isolated ambulatory hypertension and higher BMI, age, serum creatinine, glucose, a higher proportion of smokers and lower clinic BP. 27, 28 A possible explanation for these conflicting results is that, in order to evaluate the impact of long-term BP control on TOD, we limited our study to a group of highly select middle-aged hypertensive patients (excluding obese, diabetic and current smokers). This choice, eliminating some of the most important pressure-unrelated factors involved in the pathogenesis of TOD (ie obesity, diabetes, aging, smoking, etc), determined the selection of a group that was certainly not representative of the hypertensive population as whole. Among possible reasons responsible for an increased daytime but normal clinic BP, in addition to the above-mentioned factors, it has been suggested that smoking habit, working conditions or physical activity may influence awake BP profile. However, in our study a questionnaire, that was part of a stuctured diary assigned to each patient during the 24-h-BP recording session, showed no differences between the two groups in self-reported physical activity, defined by a three-level scale ranging from sedentary to mild and moderate (data not shown). A significantly higher average home BP was found in patients with isolated ambulatory hypertension and this indicates that uncontrolled BP during daily life was associated with a suboptimal BP control also under this circumstance. Third, the different changes in cardiac and renal TOD between the two groups were unrelated to different degrees of LV and renal involvement at baseline or to the extent of clinic BP variations, because the mean fall in SBP/DBP was virtually identical, but rather related to the achieved ABP. This implies that cardiovascular pressor load may often be underestimated by random clinic readings and a notable fraction of patients in whom the antihypertensive treatment is driven by clinic BP may have somewhat elevated daytime ABP values. This phenomenon reflects an enhanced pressor reactivity, induced by psychophy- 19 According to this BP threshold, almost all patients (95%) showed controlled BP values at home and despite a strong correlation between home and ABP (data not shown), this criterion had a marginal value in predicting ambulatory hypertension. Second, it is likely that the persistence of TOD observed also in subjects with effective BP control, according to clinic and out of clinic criteria, may depend on sympathetic, hormonal or other factors unrelated to haemodynamic load or alternatively, to the fact that in some patients, cardiovascular alterations are not fully reversible.
Strengths and limitations
The strengths and limitations of our study can be summarized as follows. The impact of isolated ambulatory hypertension on TOD in treated hypertensives was analysed as changes of continuous or categorical variables with respect to baseline data and this design provides more reliable information in comparison to cross-sectional analyses. The lack of pretreatment TOD parameters in such studies cannot exclude the possibility that, in patients with isolated ambulatory hypertension, cardiac mass and/or UAE were initially higher than in those with both clinic and out-of-clinic BP control. 29 We relied on several follow-up visits to estimate the degree of BP control over the entire follow-up period, and one of the main inclusion criteria was the evidence of satisfactory clinic BP control in the previous 12 months. Finally, the effect of antihypertensive therapy on BP status was assessed by clinic, multiple home and ambulatory BP measurements. Some limitations also deserve to be mentioned. Baseline data on hypertension-induced TOD pertain to a nonhomogeneous group of untreated and unsatisfactorily treated patients; however, the proportion of previously untreated and treated did not differ in subjects with or without ambulatory hypertension. A large proportion of the patients had not undergone home BP and, more importantly, ABP monitoring at baseline, and this finding limits the interpretation of the results. Another limitation, which applies to most published studies, is categorizing patients into subgroups on the basis of ambulatory and clinic BP. The cutoff for elevated daytime BP in the present study (X132/85 mmHg) has been proposed in the PAMELA study (22) and is also close to daytime normality in different populations. 30 In conclusion, a growing body of evidence indicates a potential clinical and prognostic adverse significance of isolated ambulatory hypertension in both untreated and, more recently, in treated subjects. A significant independent association between such a BP profile with an excess of TOD 16, 27, 31 and cardiovascular events 17 has been shown in untreated patients. An indication that ABP measurements during treatment are superior to office BP measurements in predicting cardiovascular risk came from a post hoc analysis provided by Verdecchia et al 32 involving 790 patients, and from a larger prospective multicentre study by Clement et al. 12 Furthermore, the relationship between ABP and TOD in treated patients hase been investigated by Mancia et al, 33 who found that the reduction of LV mass in patients with cardiac hypertrophy is more closely related to a decrease in ABP than to a decrease in clinic BP. Finally, Schillaci et al 34 have demonstrated that treated hypertensive patients with greater 24-h ABP values than office BP were more likely to develop LVH. Our data add a new piece of information on this matter suggesting that isolated ambulatory hypertension is a clinical finding associated with a significantly higher persistence of cardiac and extracardiac TOD and that achieving BP targets according to clinic criteria may have a limited impact in lowering cardiovascular organ damage.
